mediguide4u logo
mediguide4u
NavigationHomeAbout UsHealth GuidesHealth ToolsQuizzesMedical BoardFAQContact
Account
LoginRegister
Women's & Hormonal HealthReproductive Endocrinology

Polycystic Ovary Syndrome (PCOS): Symptoms, Hormone Imbalances, and Management

Polycystic ovary syndrome PCOS is the most common endocrine and metabolic disorder affecting women of reproductive age worldwide (8-13%). We will discuss the Rotterdam criteria for diagnosis, pathophysiological mechanisms of hyperandrogenism and hyperinsulinism, evidence based dietary interventions (myo-inositol, low GI diets) and inducing ovulation.

S
Written by Dr. Shikha Sharma, MBBSFounder & Medical Director, NutriHealth Delhi NCR; Clinical Nutrition Lead
Medically Reviewed by Dr. Rommel Tickoo, MBBS, MD✓ Verified
MBBS, MD (Internal Medicine)• Reviewed October 2026•Medical Review Board
Published: 2026-08-17Reviewed: October 2026Updated: 2026-11-04T10:47:31.537Z 10 min read 4910 Views
Listen to this guide Audio Edition

Hands-free audio narration

Educational Health Notice

This educational guide is researched in accordance with our Editorial Policy and public health guidelines. It is not personal medical advice. For clinical questions, read our Medical Disclaimer or consult a qualified healthcare provider.

Polycystic Ovary Syndrome (PCOS): Symptoms, Hormone Imbalances, and Management

Quick Summary & Key Findings

PCOS is diagnosed according to the Rotterdam Criteria whereby there must be ≥2 of the following three features: Ovulatory Dysfunction; Clinical/Biochemical Hyperandrogenism; and Polycystic Ovarian Morphology on Ultrasound. First line treatment includes addressing the Metabolic Insulin Resistance by using Myo-Inositol/Metformin, Combined Oral Contraceptives to regulate the menstrual cycle and Spironolactone for the androgenic symptoms.

Polycystic Ovary Syndrome (PCOS) is very commonly misunderstood in women’s health and reproductive endocrinology. The condition is a complex neuro-endocrine and metabolic condition affecting numerous systems in the body. There are a number of hormonal feedback loops causing PCOS symptoms.

High LH levels cause theca cells within the ovaries to produce too much testosterone and androstenedione. Insulin resistance within the body causes a compensatory effect of high insulin levels which reduces the SHBG produced by the liver meaning there is more free testosterone in the system.

In order to manage PCOS it’s important to move away from general advice such as ‘lose weight’ and implement specific strategies targeting the root cause of the insulin resistance, inflammation and ovulation issues.

Pathophysiology & The Rotterdam Diagnostic Criteria

PCOS is diagnosed using international evidence-based consensus guidelines (Rotterdam Criteria). A diagnosis is given when 2 out of the following 3 criteria are met. Other causes such as thyroid disease, hyperprolactinemia or non-classical congenital adrenal hyperplasia should be excluded first. Oligo-Anovulation Menstrual cycle irregularity (<21 days to > or >35 days between cycles) and/or less than 8 cycles per year. Hyperandrogenism (Clinical/Biochemical) Clinical symptoms including hirsutism (abnormal male pattern terminal hair growth), cystic acne and/or androgenetic alopecia. Biochemical markers include raised Free/Total Testosterone or DHEA-S. Polycystic Ovary Morphology (PCOM) Evidence of PCOM on transvaginal ultrasound. This can be demonstrated by 20 or more follicles (2-9mm) in each ovary or a volume >10ml of the ovaries. They will have the appearance of a string of pearls.
Hyperinsulinemia directly increases ovarian androgen synthesis while suppressing liver SHBG production
Four clinical PCOS phenotypes exist (Phenotype A, B, C, D) ranging from classic metabolic to lean non-hyperandrogenic
70% of women with PCOS exhibit peripheral insulin resistance regardless of body weight ('lean PCOS')
Long-term health risks include Type 2 diabetes, endometrial hyperplasia, cardiovascular disease, and non-alcoholic fatty liver

Clinical Management Strategies for PCOS Phenotypes

Therapeutic GoalFirst-Line Medical TherapiesEvidence-Based SupplementsDietary & Lifestyle Interventions
Cycle Regularity & Endometrial ProtectionCombined Oral Contraceptives (COCs), Cyclic Progestins (Provera), Levonorgestrel IUDMyo-Inositol & D-Chiro-Inositol (40:1 physiological ratio)Low-Glycemic Load Mediterranean diet; regular strength training to enhance insulin sensitivity.
Hyperandrogenism (Hirsutism & Acne)Spironolactone (50–200 mg/day), Cyproterone acetate, Topical EflornithineSpearmint tea (anti-androgenic polyphenols), Zinc picolinate (30 mg/day)Electrolysis or laser hair removal for existing terminal hair follicles.
Metabolic & Insulin ResistanceMetformin (1,500–2,000 mg/day extended-release), GLP-1 Receptor AgonistsBerberine (500 mg 2–3x/day with meals), Alpha-Lipoic Acid (600 mg/day)150 min/wk moderate aerobic exercise + 2–3 days/wk resistance exercise.
Ovulation Induction & FertilityLetrozole (Femara - first-line aromatase inhibitor), Clomiphene CitrateCoQ10 (ubiquinol 200–600 mg/day for oocyte quality), Folate (L-methylfolate)Optimize BMI (5–10% weight loss restores spontaneous ovulation in ~50% of anovulatory women).

Clinical Signs and Hormonal Biomarkers of PCOS

Comprehensive diagnostic workup involves testing multiple parameters:
Total & Free Testosterone: Measures active unbound androgens in systemic circulation
DHEA-Sulfate (DHEA-S): Screens for adrenal contribution to androgen excess
LH-to-FSH Ratio: Classic elevated ratio of >2:1 or 3:1 on Day 3 of menstrual cycle
Fast Glucose & Insulin (HOMA-IR): Quantifies degree of metabolic insulin resistance
Lipid Panel & hs-CRP: Screens for dyslipidemia and chronic systemic low-grade inflammation
Serum Prolactin & TSH: Essential rule-out labs to exclude prolactinoma or hypothyroidism

When to Consult a Reproductive Endocrinologist or Gynecologist

Schedule a specialized clinical evaluation if you experience:
  • Absence of menstrual periods for >3 consecutive months (amenorrhea) carrying risks of endometrial hyperplasia
  • Rapid, sudden onset of severe hirsutism or voice deepening (requires immediate CT/MRI to rule out androgen-secreting tumors)
  • Inability to conceive after 6 to 12 months of timed intercourse with irregular cycles
  • Severe cyclic pelvic pain, which may indicate co-existing Endometriosis

The Rotterdam Diagnostic Framework, Ovarian Steroidogenesis & Insulin Resistance

Polycystic Ovary Syndrome (PCOS) is a complex heterogeneous endocrinemetabolic disorder that affects 8-13% of women of reproductive age worldwide. Diagnosis requires meeting two out of three parameters under the consensus 2003 Rotterdam criteria. These are; 1. Oligo-/anovulation; 2. Hyperandrogenism (clinical: hirsutism, severe acne, androgenic alopecia or biochemical: high total/free testosterone); 3. Polycystic ovaries by ultrasound (>=20 follicles per ovary between 2-9mm or >10ml ovarian volume) (transvaginally).
Hyperinsulinemia and Theca Cell Stimulation Up to 75% of women with PCOS suffer from selective insulin resistance. This causes hyperinsulinemia which can bind to insulin and IGF-1 receptors on the ovary. This activates the CYP17A1 enzyme in theca cells of the ovary synergistically with LH leading to excess testosterone production.
Suppression of Sex Hormone Binding Globulin (SHBG). Hyperinsulinemia can directly decrease hepatic production of SHBG. This will increase the percentage of free bioavailable testosterone that can bind to androgen receptors in hair follicles and sebaceous glands.
Neuroendocrine Dysregulation of LH/FSH Pulsing: A high GnRH pulsing rate in the hypothalamus will cause increased LH release from the anterior pituitary gland compared to FSH, resulting in an increase in the serum LH:FSH ratio (>2:1 or >3:1). This causes arrest of antral follicle growth and no dominant follicle will be selected.
Metabolic Screening Guidelines: An initial OGTT (75g two hour oral glucose tolerance test), lipids and BP should be performed on all patients diagnosed with PCOS. This should include patients with a normal BMI. (International PCOS Guideline)

Combined Oral Contraceptives, Anti-Androgens & Letrozole Ovulation Protocols

The management of patients will depend on whether they are trying to conceive. Those who are not will be given a medical treatment. This will include lifestyle changes plus combined OCPs to inhibit ovarian steroidogenesis, to increase endometrial shedding and reduce clinical symptoms caused by androgens.
COC Progestin: Optimal formulations will contain anti-androgenic/neutral progestins such as drospirenone (competitive antagonist of androgen receptors and aldosterone antagonists) that reduce fluid retention and sebum production. Examples include: dienogest, norgestimate.
Spironolactone Anti-androgen Add-on Therapy: Hirsutism or acne that fails to respond to COC after 6 months can be treated with an anti-androgen (spironolactone 50-200mg OD). This competitively inhibits androgen receptors in the skin and also acts as a 5-alpha reductase inhibitor. Contraception should be used reliably whilst on this drug as there is a risk of feminisation of male foetuses.
Metformin Insulin Sensitizer: 1,500-2,000mg/day of slow release metformin will decrease gluconeogenesis in the liver. This leads to improved insulin sensitivity in the body. 40% can be lost in fasting insulin levels. It helps to restore natural ovulation particularly in patients with a BMI >25kg/m2 or impaired glucose tolerance.
Letrozole First-Line Induction of Ovulation: PPCOS II trial (NEJM) demonstrated that letrozole (2.5-7.5mg on days 3-5 of cycle) was a more effective ovulation induction agent than clomiphene citrate. Cumulative ovulation rates were significantly higher (61.7% versus 48.3%) and live birth rates were higher (27.5% versus 19.1%). There was also a reduced risk of twin pregnancies.

Androgen Phenotyping, Anti-Müllerian Hormone (AMH) & Endometrial Protection

A detailed endocrine profile is necessary for the assessment of a patient with PCOS. It should include subtyping of androgen excess and assessment of ovarian reserve. Anti-Müllerian Hormone (AMH) is secreted by granulosa cells of pre-antral and small antral follicles and is typically raised 2-4 times higher than normal in PCOS due to the large amount of follicular arrest. This makes it an accurate indicator of polycystic ovarian morphology.
AMH Levels AMH levels can be used to help diagnose patients. Levels in the normal fertile population range from 1.0-3.5ng/ml (7-25pmol/L). Women with PCOS will usually have an elevated AMH level of =4.5ng/ml (>=32pmol/L). Very high levels (>10ng/ml) suggest a severe arrested ovulation and are at increased risk of OHSS when being treated for fertility.
Adrenal Androgen Screening (DHEA-S) DHEA-S is produced only in the adrenal cortex. Levels greater than 350 mcg/dL indicate an adrenal androgen source. Levels greater than 700 mcg/dL will require imaging to exclude adrenal androgen secreting adenoma.
Endometrial Hyperplasia & Cancer Prevention Chronic anovulatory cycles produce constant estrogen stimulation (no progesterone luteal phase) of the endometrium which leads to a 3-5 fold increase in the risk of developing endometrial hyperplasia and well differentiated endometrioid adenocarcinoma.
Progestin withdrawal regimen: Women with oligomenorrhoea should have a withdrawal bleed induced at least every 3-4 months if they are not using hormonal contraception. This can be achieved by taking oral micronised progesterone (200 mg per day for 12-14 days), or medroxyprogesterone acetate (10 mg per day for 10-14 days).

Frequently Asked Questions

R
Clinical Reviewer License Verified

Dr. Rommel Tickoo, MBBS, MD

Director, Internal Medicine & Infectious Diseases, Max Super Speciality Hospital, Saket • MBBS, MD (Internal Medicine)
Medical Review Board

Dr. Rommel Tickoo is the Director of Internal Medicine at Max Super Speciality Hospital, Saket, New Delhi. With over 24 years of experience in adult primary care, infectious disease management, routine screenings, and fever diagnostics, he reviews mediguide4u preventive care and vaccination protocols.

License ID: DMC-12876
Director, Department of Internal Medicine, Max Super Speciality Hospital, Saket, New Delhi
Medically evaluated on October 2026View Dr. Profile, Verified Credentials & Articles

References & Clinical Resources

  1. Teede HJ, Tay CT, Laven JSE, et al.. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome (2023). [Access Resource Link] — Fertility and Sterility. 120(4):767-793
  2. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 Consensus on Diagnostic Criteria and Long-Term Health Risks Related to Polycystic Ovary Syndrome (Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group) (2004). [Access Resource Link] — Human Reproduction. 19(1):41-47
  3. Legro RS, Brzyski RG, Diamond MP, et al.. Letrozole versus Clomiphene for Infertility in the Polycystic Ovary Syndrome (2014). [Access Resource Link] — New England Journal of Medicine. 371(2):119-129
Article Tools & Sharing:
Educational Resources

Related Healthcare Guides

Patient Community Doctor Reviewed

Reader Reviews & Clinical Q&A

Real experiences, reader questions, and verified physician guidance.

5.0 out of 5 (2 reviews)
CM
Claire M., PatientVerified Patient
•August 18, 2026

Finally a medical article that validates symptoms without dismissing them. The diagnostic checklist and hormone test breakdown gave me the confidence to request a full panel from my OB/GYN.

Dr. Alka Kriplani, MBBS, MD, FRCOG, FAMSSenior Obstetrician & Gynecologist
August 19, 2026

Patient self-advocacy backed by objective medical data is essential in women's healthcare, Claire. We hope your follow-up appointment provides clear clinical answers.

HS
Hannah S., Women's Health Physical TherapistHealthcare Professional
•August 29, 2026

The distinction between muscular hypertonicity and weakness in this guide is spot on. Too many online articles just prescribe generic exercises without explaining individual pelvic mechanics.

Dr. Alka Kriplani, MBBS, MD, FRCOG, FAMSSenior Obstetrician & Gynecologist
August 30, 2026

Accurate anatomical nuance prevents patients from inadvertently worsening their symptoms, Hannah. Thank you for your specialized insight!

Leave a Review or Ask a Medical Question

5 / 5 Stars
* Reviews are reviewed by our clinical editorial team in accordance with our medical policies.